Physician profile
Fernando L Silva
NPI 1881797355
$6,777.17
in general payments reported to CMS, 2019-2025
26 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,480 · 2020: $689 · 2021: $1,070 · 2022: $738 · 2023: $911 · 2024: $805 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,800.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,077.03 | 2022-2025 | Infuse, Miebo, Xiidra |
| Abbvie INC. | $800.64 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $773.44 | 2019-2021 | |
| Alcon Vision LLC | $673.69 | 2019-2025 | Simbrinza, Clareon, Tryptyr |
| Allergan, INC. | $579.86 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $521.30 | 2019-2025 | |
| Aerie Pharmaceuticals, INC. | $497.35 | 2019-2021 | |
| Oyster Point Pharma, INC. | $316.17 | 2023-2025 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $246.05 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $238.32 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $145.98 | 2020-2023 | |
| Eyevance Pharmaceuticals LLC | $141.15 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $125.71 | 2024-2025 | Xdemvy |
| Maculogix, INC. | $114.61 | 2020 | |
| Mallinckrodt Hospital Products INC. | $113.74 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $111.10 | 2019 | |
| Abb Con-Cise Optical Group LLC | $68.57 | 2020 | |
| Thea Pharma INC. | $48.72 | 2024-2025 | Iyuzeh |
| Harrow Eye, LLC | $37.60 | 2025 | Vevye |
| Astrazeneca Pharmaceuticals LP | $34.26 | 2024-2025 | Imfinzi |
| Biotissue Holdings INC. | $30.74 | 2020-2024 | |
| Kite Pharma, INC. | $21.94 | 2023 | Yescarta |
| Alnylam Pharmaceuticals INC. | $18.07 | 2023 | Givlaari |
| Coopervision INC. | $14.85 | 2023 | Biofinity Contact Lens |
| Akorn, INC. | $13.57 | 2020 | |
| Dova Pharmaceuticals | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.